Spiro George Rombotis - 31 Jan 2023 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Role
President and CEO, Director
Signature
/s/ Spiro Rombotis
Issuer symbol
CYCC
Transactions as of
31 Jan 2023
Net transactions value
$0
Form type
4
Filing time
02 Feb 2023, 15:18:24 UTC
Previous filing
16 Dec 2021
Next filing
03 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYCC Common Stock Award $0 +57,600 +1155% $0.000000 62,588 31 Jan 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person received an award of 57,600 restricted stock units on January 31, 2023, which shall vest in full on January 31, 2026, provided, however, that if certain clinical milestones are achieved then such restricted stock units shall vest in full earlier in connection with such achievement.
F2 Includes 4,988 shares of common stock and 57,600 restricted stock units.